Our preliminary data in HNSCC models spurred interest in a possible role of wild-type HRAS in innate resistance to standard-of-care drugs such as cisplatin and cetuximab as well as targeted agents in clinical development in HNSCC, including CDK4/6 inhibitors and PI3K pathway drugs. Here, HRAS is linked to head and neck squamous cell carcinoma.